EXAS - イグザクト・サイエンシズ （Exact Sciences Corporation） イグザクト・サイエンシズ

Exact Sciences is shifting its focus towards achieving positive adjusted EBITDA as a way to signal a path to eliminate cash burn. Here''s my take on EXAS stock.

Exact Sciences is beginning to stem losses and is continuing to grow revenue at a reasonable clip. Click here to find out why EXAS stock is a Sell.

Exact Sciences Corporation (NASDAQ:EXAS) price on Friday, February 24, fall -1.90% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $60.46. A look at the stock’s price movement, the level at last check in today’s session was $61.63, moving within a range at $60.58 and $68.00. The beta … Unlocking Growth Opportunity In Exact Sciences Corporation (NASDAQ: EXAS) Read More »

Exact Sciences (EXAS) announced on Thursday a debt exchange transaction and a private placement of convertible senior notes.Pursuant to an exchange and purchase agreement entered with…

Largely driven by increased sales of its flagship at-home colorectal cancer screening test Cologuard, Madison-based cancer screening firm Exact Sciences Corp. posted record revenue in 2022 and surpassed analysts'' expectations for revenue and earnings in the fourth quarter.

Since the launch of OpenAI ‘s ChatGPT, artificial intelligence (AI) has risen to the top of the year’s important trend list. The United States government has already prioritized it, joining forces with the European Union to help experts work to develop AI tools even further. This has already created a tremendous opportunity for investors , sending AI stocks onto an impressive month-long surge that shows no signs of slowing down. But investors shouldn’t be focusing solely on companies building AI systems and tools. Cathie Wood has identified a stock that she thinks will give investors the exposure to the booming AI market that they need and it isn’t C3.ai (NYSE: AI ) or Splunk (NASDAQ: SPLK ). Wood sees the biggest opportunity in Tesla (NASDAQ: TSLA ). If she’s correct in her bullish thesis on it, TSLA stock will be among the year’s winners. Let’s take a closer look at the electric vehicle (EV) leader and why Wood sees it as a great AI bet. TSLA Stock in an AI-Driven World Why does Wood think TSLA stock is a potential winner of the AI boom?

In the last trading session, 2.31 million shares of the Exact Sciences Corporation (NASDAQ:EXAS) were traded, and its beta was 1.39. Most recently the company’s share price was $67.45, and it changed around -$3.32 or -4.69% from the last close, which brings the market valuation of the company to $12.57B. EXAS currently trades at a … Why Exact Sciences Corporation (NASDAQ: EXAS) Is A Stock Not To Be Discarded In 2023 Read More »

Cathie Wood. David Swanson/Reuters ChatGPT has excited investors'' imagination on AI, according to Ark Invest''s Cathie Wood. But Tesla and Exact Sciences are poised to become…

Cathie Wood. David Swanson/Reuters ChatGPT has excited investors'' imagination on AI, according to Ark Invest''s Cathie Wood. But Tesla and Exact Sciences are poised to become big winners from artificial intelligence, she said. "We believe that the hidden gems that will benefit the most from artificial intelligence are those companies with proprietary datasets." The rise of ChatGPT has spurred excitement on Wall Street, but don''t overlook other innovators in artificial intelligence, said Ark Invest''s Cathie Wood. In an interview with Yahoo Finance Live on Thursday , Wood said she''s pleased to see that ChatGPT has captured the imagination of investors, who mostly have not been buying companies that prioritize innovation. She sees AI delivering productivity gains and pointed to Facebook parent Meta Platforms highlighting the technology as a way to drive efficiency. For its part, ChatGPT has shown a capacity for a range of tasks, such as writing stock stories , layoff emails , and even dating-app messages .

The stock is full of potential -- and risk.

In last trading session, Exact Sciences Corporation (NASDAQ:EXAS) saw 1.74 million shares changing hands with its beta currently measuring 1.27. Company’s recent per share price level of $39.39 trading at -$1.19 or -2.93% at ring of the bell on the day assigns it a market valuation of $6.48B. That closing price of EXAS’s stock is … Exact Sciences Corporation (NASDAQ:EXAS) Has Recovered 10.28% So Far, But Another -306.19% Loss Cannot Be Ruled Out Read More »

Exact Sciences Corp. (EXAS) shares closed this week 20.1% lower than it did at the end of last week. The stock is currently down 54.2% year-to-date, down 70.4% over the past 12 months, and up 10.4% over the past five years. This week, the Dow Jones Industrial Average fell 7.2%, and the S&P 500 fell 8.7%. Trading Activity Shares traded as high as $43.44 and as low as $35.34 this week.Shares closed 72.4% below its 52-week high and 4.8% above its 52-week low.Trading volume this week was 8.7% lower than the 10-day average and 8.5% higher than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 48.1% The company's stock price performance over the past 12 months lags the peer average by 61.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Many of these Cathie Wood stocks have faced significant challenges in the first half of 2022. Wood’s innovation-focused exchange-traded funds (ETFs) were all the rage on Wall Street until the recent market downturn. As Bloomberg recently reported, “Wood and her firm ARK Investment Management have been among the highest-profile victims of a stock selloff that has swept Wall Street as inflation takes off and the Federal Reserve raises borrowing costs.” Investors have been keeping away from riskier technology stocks in favor of established industries that deliver steady profits. As a result, Wood’s flagship ARK Innovation ETF (NYSEARCA: ARKK ) has fallen 50% year-to-date (YTD), whereas the S&P 500 and the NASDAQ 100 indices have only declined 11.9% and 17.4%, respectively. The recent rout in technology stocks is undeniably significant. But if history is any guide, these declines will also be temporary. Innovation will continue to be a primary driving force of the modern economy. Accordingly, our readers might want to capitalize on the current selloff to invest in tech innovators at discount prices. 7 Top-Rated Large-Cap Stocks to Buy and Hold With that information, here are the five best Cathie Wood Stocks to buy in June: Ticker Company Price EXAS Exact Sciences Corporation $47.71 IONS Ionis Pharmaceuticals, Inc. $34.74 KTOS Kratos Defense & Security Solutions, Inc. $14.69 TRMB Trimble Inc. $66.57 PATH UiPath Inc. $21.12 Cathie Wood Stocks to Buy: Exact Sciences (EXAS) Source: Tada Images / Shutterstock 52-week range: $45.25 – $133.99 Biotech group Exact Sciences (NASDAQ: EXAS ) focuses on the early detection and treatment guidance for cancer.

Exact Sciences (NASDAQ: EXAS ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 1 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 2 2 0 0 0 3M Ago 0 0 0 0 0 In the last 3 months, 5 analysts have offered 12-month price targets for Exact Sciences. The company has an average price target of $81.0 with a high of $95.00 and a low of $50.00. Below is a summary of how these 5 analysts rated Exact Sciences over the past 3 … Full story available on Benzinga.com

MADISON, Wis., May 27, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that company management will participate in the following conferences and invited investors to participate by webcast. William Blair 42nd Annual Growth…